Industry
Medical - Devices
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Loading...
Open
33.71
Mkt cap
2B
Volume
3.3M
High
33.97
P/E Ratio
-14.64
52-wk high
53.69
Low
29.90
Div yield
N/A
52-wk low
13.82
Portfolio Pulse from Benzinga Newsdesk
November 02, 2023 | 12:49 pm
Portfolio Pulse from Benzinga Insights
November 01, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2023 | 8:39 pm
Portfolio Pulse from totan@benzinga.com
November 01, 2023 | 8:14 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2023 | 3:57 pm
Portfolio Pulse from Benzinga Newsdesk
October 11, 2023 | 7:38 pm
Portfolio Pulse from Benzinga Insights
October 02, 2023 | 8:00 pm
Portfolio Pulse from Vandana Singh
September 15, 2023 | 5:46 pm
Portfolio Pulse from Benzinga Newsdesk
September 15, 2023 | 4:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.